Fu Zhenkun, Chen Shuang, Liu Shengwei, Han Shaoli, Gao Xiang, Li Dalin, Li Dianjun
Heilongjiang Provincial Key Laboratory for Infection and Immunity, Harbin Medical University and Heilongjiang Academy of Medical Science, 150081 Harbin, China.
Department of Immunology, Harbin Medical University and Heilongjiang Academy of Medical Science, 150081 Harbin, China.
Oncotarget. 2016 Sep 6;7(36):57970-57977. doi: 10.18632/oncotarget.11153.
Decoy Receptor 3 (DcR3), also called TNFRSF6β, is a member of the tumor necrosis factor receptor superfamily and is a soluble receptor for FasL. DcR3 is overexpressed in cancers and contributes to tumorigenesis through immune suppression and promotion of angiogenesis. We found that DcR3 is overexpressed in breast infiltrating ductal carcinoma (IDC) cells as compared with normal controls. We also conducted a case-control study analyzing associations of DcR3 polymorphisms with breast IDC risk. Subjects included 531 females with breast IDC and 592 age-matched healthy controls. Four DcR3 single nucleotide polymorphism loci with minor frequencies of more than 5% (rs3208008, rs41309931, rs2297441 and rs1291207) were genotyped using polymerase chain reaction restriction fragment length polymorphism and sequencing. Our results revealed significant differences in rs41309931genotypes and alleles (P < 0.01). Based on Haploview software analysis, the haplotype block Ars3208008 Grs41309931 Grs2297441 Ars1291207 exhibited the highest frequency, but, haplotype blocks Ars3208008 Trs41309931 Grs2297441 Ars1291207 and Crs3208008 Grs41309931 Grs2297441 Ars1291207 were associated with breast IDC risk. This study also detected associations between DcR3 gene polymorphisms and the clinicopathological features of breast IDC, including lymph node metastasis and C-erbB2, P53, estrogen receptor and progesterone receptor status. These data indicate that DcR3 gene polymorphisms are associated with sporadic breast IDC risk in Northeast Chinese females.
诱饵受体3(DcR3),也称为TNFRSF6β,是肿瘤坏死因子受体超家族的成员,是FasL的可溶性受体。DcR3在癌症中过度表达,并通过免疫抑制和促进血管生成促进肿瘤发生。我们发现,与正常对照相比,DcR3在乳腺浸润性导管癌(IDC)细胞中过度表达。我们还进行了一项病例对照研究,分析DcR3基因多态性与乳腺IDC风险的关联。研究对象包括531名患有乳腺IDC的女性和592名年龄匹配的健康对照。使用聚合酶链反应-限制性片段长度多态性和测序对四个次要频率超过5%的DcR3单核苷酸多态性位点(rs3208008、rs41309931、rs2297441和rs1291207)进行基因分型。我们的结果显示rs41309931基因型和等位基因存在显著差异(P < 0.01)。基于Haploview软件分析,单倍型块Ars3208008 Grs41309931 Grs2297441 Ars1291207频率最高,但单倍型块Ars3208008 Trs41309931 Grs2297441 Ars1291207和Crs3208008 Grs41309931 Grs2297441 Ars1291207与乳腺IDC风险相关。本研究还检测到DcR3基因多态性与乳腺IDC临床病理特征之间的关联,包括淋巴结转移以及C-erbB2、P53、雌激素受体和孕激素受体状态。这些数据表明,DcR3基因多态性与中国东北女性散发性乳腺IDC风险相关。